Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial

N Nan Niu J Jinqi Xue G Guanglei Chen F Fang Qiu Q Qianshi Xu X Xinyu Zheng C Chao Liu Y Yafei Zhao X Xi Gu Y Yi Zhao (State Key Laboratory of Quantum Functional Materials, School of Physical Science and Technology) H Hong Xu (Institute of Nuclear and New Energy Technology) H Hao Zhang G Guijin He K Ke Li P Pengfei Li X Xiaoying Chen Y Yong Li S Shuo Wang D Demiao Zhu T Tong Liu F Fei Xing Y Yongqing Xu Y Ye Han M Meiyue Tang M Mingxin Liu (Department of Chemistry) G Gege Jiao X Xiaofan Jiang (Beijing National Laboratory for Molecular Science, State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and Molecular Engineering) T Tony Yuen Z Zheng Pang C Caigang Liu